---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-017822"
form_type: "8-K"
ticker: "CYTK"
cik: "0001061983"
company_name: "CYTOKINETICS INC"
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T19:42:30.563872+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cytokinetics Q1 net loss widens to $131.3M; omecamtiv CRL; cuts spend 10%

## Summary
- Net loss of $131.3M ($1.38/shr) vs $89.4M ($1.05) in Q1 2022; revenue $4.6M (up from $1.1M).
- Cash $704.4M; plans to reduce 2023 spending >10% to maintain >2 years cash runway.
- FDA issued Complete Response Letter for omecamtiv mecarbil NDA; EMA MAA review ongoing.
- SEQUOIA-HCM enrollment nearly complete; top-line results expected Q4 2023.
- COURAGE-ALS met futility criteria; company discontinuing reldesemtiv treatment.

## SEC filing metadata
- accession: 0000950170-23-017822
- form_type: 8-K
- ticker: CYTK
- cik: 0001061983
- company_name: CYTOKINETICS INC
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1061983/000095017023017822/0000950170-23-017822-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061983/000095017023017822/cytk-20230504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-017822
- JSON: https://secwatch.observer/filing/0000950170-23-017822.json
- Plain text: https://secwatch.observer/filing/0000950170-23-017822.txt

## Key facts
- Earnings Releases
  CYTOKINETICS INC reported the first quarter ended March 31, 2023 results: net income $131.3 million, EPS $1.38 per share.
  - Period: the first quarter ended March 31, 2023
  - Net income: $131.3 million
  - EPS: $1.38 per share
  - Result: reported results
  source text: Net loss for the first quarter was $131.3 million, or $1.38 per share, compared to net loss for the first quarter of 2022 of $89.4 million, or $1.05 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1061983/000095017023017822/0000950170-23-017822-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.